May 20, 2021 Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer
May 13, 2021 Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
May 10, 2021 Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
May 7, 2021 Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
Apr 29, 2021 Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting
Apr 12, 2021 Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting
Apr 8, 2021 Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference
Apr 5, 2021 Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors
